Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 15, No. 10, 2016, pp. 2219-2225
Bioline Code: pr16292
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 15, No. 10, 2016, pp. 2219-2225
© Copyright 2016 - Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.
A new spectrofluorimetric assay method for vandetanib in tablets, plasma and urine|
Darwish, Hany W & Bakheit, Ahmed H
Purpose: To develop a simple and sensitive spectrofluorimetric method for the determination of
vandetanib (VDB) in tablets (containing 100 mg of the drug) and biological fluids (spiked human plasma
Methods: The proposed method is based on examining the intrinsic fluorescence intensity of VDB in
acetonitrile at 480 nm after excitation at 330 nm. Factors affecting fluorescence intensity of the cited
drug (VDB), including the influence of pH, diluting solvent and time, were studied and optimized by one
factor at a time approach. A calibration curve was constructed by plotting VDB fluorescence intensity at
480 nm versus VDB concentrations in ng mL-1. The method was validated according to the
recommendations of International Conference on Harmonisation (ICH) for validation of the analytical
Results: The linearity range of the method was 20 – 600 ng mL-1, with limits of quantification (LOQ) and
of detection (LOD) of 30.45 and 10.05 ng mL-1, respectively. The adopted method was applied
successfully to the quantitation of VDB in pure powder form (100.90 ± 0.91 %), laboratory prepared
tablets (97.86 ± 1.42 %), spiked human plasma (97.97 ± 2.36 %) and urine (97.59 ± 0.87 %).
Comparison of the proposed method with that of liquid chromatography-tandem mass spectrometry
showed that there was no significant difference (p < 0.05) between the two methods in terms of
accuracy and precision.
Conclusion: The proposed method is simple and highly sensitive and, consequently, can be applied to
assay VDB in biological samples as well as in dosage form.
Vandetanib; Spectrofluorimetry; Assay; Validation; Human plasma; Human urine; Dosage forms
Alternative site location: http://www.tjpr.org